X

Drug Profile

ALG 055009

Alternative Names: ALG-009; ALG-055009; ALG-THR-β; THR-Beta agonist - Aligos Therapeutics; THR-β-agonists - Aligos Therapeutics

Latest Information Update: 19 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aligos Therapeutics
Class Hepatoprotectants; Small molecules
Mechanism of Action Thyroid hormone receptor beta agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Non-alcoholic steatohepatitis

Most Recent Events

19 Dec 2024 Chemical structure information added.
19 Sep 2024 ALG 055009 is available for licensing as of 19 Sep 2024. http://www.aligos.com
19 Sep 2024 Aligos Therapeutics plans a phase IIb trial for Non-alcoholic-steatohepatitis in middle of 2025 (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com